Shilpa Medicare receives Europe approval for Amifampridine Tablets, 10 mg

This product has sales of about US$ 20 million in Europe

Shilpa Medicare Limited has received Marketing Authorization from Germany, EU for Amifampridine Tablets, 10 mg under the National Procedure.

Amifampridine is used as a drug, predominantly in the treatment of a number of rare muscle diseases. Specifically, Amifampridine is used to treat Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disease.

This product has sales of about US$ 20 million in Europe. As on date, there is one other approved generic in the market.